Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan.
Int J Mol Sci. 2017 Dec 29;19(1):98. doi: 10.3390/ijms19010098.
An adequate blood supply is essential for cancer cells to survive and grow; thus, the concept of inhibiting tumor angiogenesis has been applied to cancer therapy, and several drugs are already in clinical use. It has been shown that treatment with those anti-angiogenic drugs improved the response rate and prolonged the survival of patients with various types of cancer; however, it is also true that the effect was mostly limited. Currently, the disappointing clinical results are explained by the existence of intrinsic or acquired resistance to the therapy mediated by both tumor cells and stromal cells. This article reviews the mechanisms of resistance mediated by stromal cells such as endothelial cells, pericytes, fibroblasts and myeloid cells, with an emphasis on fibrocytes, which were recently identified as the cell type responsible for regulating acquired resistance to anti-angiogenic therapy. In addition, the other emerging role of fibrocytes as mediator-producing cells in tumor progression is discussed.
充足的血液供应对于癌细胞的存活和生长至关重要；因此，抑制肿瘤血管生成的概念已被应用于癌症治疗，并且已有几种药物在临床使用。已经表明，用这些抗血管生成药物治疗可提高各种类型癌症患者的反应率并延长其生存期；然而，事实也是如此，这种效果大多是有限的。目前，临床结果令人失望，其原因是肿瘤细胞和基质细胞介导的治疗存在内在或获得性耐药。本文综述了基质细胞（如内皮细胞、周细胞、成纤维细胞和髓样细胞）介导的耐药机制，重点介绍了最近被确定为调节抗血管生成治疗获得性耐药的细胞类型纤维细胞。此外，还讨论了纤维细胞作为产生介质的细胞在肿瘤进展中的另一个新兴作用。
